Question

A middle-aged male patient presents with protrusion of the chin, excessive sweating, impaired glucose tolerance, and enlargement of hands and feet. Which of the following is a growth hormone receptor antagonist used to treat this condition?

• A. Octreotide
• B. Pegvisomant
• C. Cabergoline
• D. Olcegepant

Answer 1

The Correct Option is B

The patient is presenting symptoms commonly associated with acromegaly, a condition caused by excessive growth hormone (GH) production. Symptoms often include protrusion of the chin, excessive sweating, impaired glucose tolerance, and enlargement of extremities. A growth hormone receptor antagonist is a medication that blocks the action of growth hormone, thus alleviating the symptoms associated with its excess.

Among the options provided:

• Octreotide: This is a somatostatin analog, not a growth hormone receptor antagonist. It works by inhibiting the release of GH.
• Pegvisomant: This drug is a growth hormone receptor antagonist. It directly blocks the effects of GH by preventing it from binding to its receptor, thereby diminishing its effects on growth and metabolism.
• Cabergoline: This medication is a dopamine agonist, which can help reduce GH level but works primarily through inhibiting pituitary hormone secretion, not as a receptor antagonist.
• Olcegepant: This is a CGRP antagonist used for migraine treatment, unrelated to growth hormone inhibition.

Given the symptoms and treatment goals, Pegvisomant is the growth hormone receptor antagonist used to treat this condition.